OBJECTIVE: To study the efficacy of neo-adjuvant chemotherapy followed by radiotherapy in advanced head and neck cancer. STUDY DESIGN: Randomised, prospective study. SETTING:Tertiary academic referral center. PATIENTS: One hundred and eighty patients of advanced head and neck squamous cell carcinoma. INTERVENTION: PATIENTS were randomized into two arms. The study arm (CT-RT arm) received 3 cycles of anterior chemotherapy with Inj. Cisplatin 100 mg/m(2) on D(1) and Inj 5F.U. 700 mg/m(2) on D(1)-D(4) at an interval of 21 days, followed by external radiation. The control arm (RT arm) received external radiotherapy only. The dose of Radiotherapy was 64 to 68 Gy in conventional fractionation. RESULTS: PATIENTS of CT-RT showed better tumour control locally than patients who received only RT. Toxicities were commoner in CT-RT arm but they were manageable. 5 year survival is higher in the CT-RT arm (21% vs 16%; p value> 0.05). CONCLUSION:Anterior chemotherapy with Cisplatin and 5F.U. is associated with good clinical response which is translated into increased survival along with acceptable toxicities.
RCT Entities:
OBJECTIVE: To study the efficacy of neo-adjuvant chemotherapy followed by radiotherapy in advanced head and neck cancer. STUDY DESIGN: Randomised, prospective study. SETTING: Tertiary academic referral center. PATIENTS: One hundred and eighty patients of advanced head and neck squamous cell carcinoma. INTERVENTION: PATIENTS were randomized into two arms. The study arm (CT-RT arm) received 3 cycles of anterior chemotherapy with Inj. Cisplatin 100 mg/m(2) on D(1) and Inj 5F.U. 700 mg/m(2) on D(1)-D(4) at an interval of 21 days, followed by external radiation. The control arm (RT arm) received external radiotherapy only. The dose of Radiotherapy was 64 to 68 Gy in conventional fractionation. RESULTS:PATIENTS of CT-RT showed better tumour control locally than patients who received only RT. Toxicities were commoner in CT-RT arm but they were manageable. 5 year survival is higher in the CT-RT arm (21% vs 16%; p value> 0.05). CONCLUSION: Anterior chemotherapy with Cisplatin and 5F.U. is associated with good clinical response which is translated into increased survival along with acceptable toxicities.
Entities:
Keywords:
Cisplatin and 5F.U.; Head & Neck Cancer; Neo-adjuvant Chemotherapy
Authors: P B Chougule; M S Akhtar; W Akerley; N Ready; H Safran; R McRae; P Nigri; J Bellino; J Koness; K Radie-Keane; H Wanebo Journal: Semin Radiat Oncol Date: 1999-04 Impact factor: 5.934
Authors: M Martin; A Hazan; L Vergnes; C Peytral; J J Mazeron; J P Sénéchaut; G Lelièvre; R Peynègre Journal: Int J Radiat Oncol Biol Phys Date: 1990-10 Impact factor: 7.038
Authors: Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan Journal: Cochrane Database Syst Rev Date: 2021-12-20